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SteatosisWhile adipose tissue-associated macrophages contribute to development of chronic inﬂammation and
insulin resistance of obesity, little is known about the role of hepatic Kupffer cells in this environment. Here
we address the impact of Kupffer cell ablation using clodronate-encapsulated liposome depletion in a diet-
induced obese (DIO) and insulin resistant mouse model. Hepatic expression of macrophage markers
measured by realtime RT-PCR remained unaltered in DIO mice despite characteristic expansion of adipose
tissue-associated macrophages. DIO mouse livers displayed increased expression of alternative activation
markers but unaltered proinﬂammatory cytokine expression when compared to lean mice. Kupffer cell
ablation reduced hepatic anti-inﬂammatory cytokine IL-10 mRNA expression in lean and DIO mice by 95%
and 84%, respectively. Despite decreased hepatic IL-6 gene expression after ablation in lean and DIO mice,
hepatic STAT3 phosphorylation, Socs3 and acute phase protein mRNA expression increased. Kupffer cell
ablation in DIO mice resulted in additional hepatic triglyceride accumulation and a 30–40% reduction in
hepatic insulin receptor autophosphorylation and Akt activation. Implicating systemic loss of IL-10, high-fat-
fed IL-10 knockout mice also displayed increased hepatic STAT3 signaling and hepatic triglyceride
accumulation. Insulin signaling was not altered, however. In conclusion, Kupffer cells are a major source
of hepatic IL-10 expression, the loss of which is associated with increased STAT3-dependent signaling and
steatosis. One or more additional factors appear to be required, however, for the Kupffer cell-dependent
protective effect on insulin receptor signaling in DIO mice.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Omental adipose tissue produces an array of adipokines including
leptin, adiponectin, resistin, and proinﬂammatory cytokines such as
IL-6 and tumor necrosis factor alpha (TNF-α) [1]. Levels of these
factors are under metabolic regulation and can individually impact
local and systemic insulin responsiveness. For instance, levels of the
proinﬂammatory cytokines IL-6 and TNF-α are elevated in the
adipose tissue of obese, insulin resistant patients [2–4] and have been
shown to directly inhibit insulin signaling through SOCS-3 induction
[5] and c-Jun-N-terminal kinase (JNK)-dependent activation [6–8]
respectively.
Adipose tissue-associated macrophages are increased in obesity
[9–11] and account for almost all of the TNF-α production and a
signiﬁcant fraction of the IL-6 produced by the adipose tissue [11,12].
This can be attributed to the increased inﬂammatory properties of the
newly recruitedmacrophages [12] as well as a shift in resident adipose
tissue-associated macrophage activation state from alternative to+1 585 756 4468.
(R.A. Mooney).
ll rights reserved.classical activation [13]. Obesity increases expression and secretion of
monocyte chemoattractant protein 1 (MCP-1/CCL2) in adipocytes and
may explain how the adipose tissue actively recruits new macro-
phages. In fact, knockout mouse models of MCP-1 or its receptor
(CCR2) have reduced macrophage accumulation and decreased
inﬂammation within the adipose tissue under high-fat diet conditions
[14,15] and in leptin receptor-deﬁcient (Lepdb) mice [16].
Macrophage stimuli can elicit varied and distinct macrophage
activation states [17]. Classical (Th1) activation is elicited in response
to inﬂammatory molecules such as LPS or TNF-α in combination with
IFN-γ and results in proinﬂammatory cytokine production and the
respiratory burst (characterized by nitric oxide production) [17]. In
contrast, alternative (Th2) activation dampens inﬂammatory
responses and is characterized by increased arginase 1 expression
and activity as well as increased expression of molecules such as MHC
class II, mannose receptor, chitinase 3-like 3 (Ym1/2), and the
resistin-like molecule FIZZ1 [17,18].
Recent investigations have focused on the phenotypic shift in
adipose tissue-associated macrophage activation state from alterna-
tive to classical that occurs during obesity. Lumeng et al. [13] demon-
strated that the predominant adipose tissue-associated macrophage
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Th2 state to proinﬂammatory Th1 in obesity. More recently, Odegaard
et al. [19] observed that loss of PPAR-γ (in the Th2-prone Balb/cmice)
impairs alternative activation of adipose tissue-associated macro-
phages, resulting in susceptibility to diet-induced obesity and
decreased insulin responsiveness via reduced β-oxidative capacity.
Kang et al. [20] demonstrated that parenchymal cell-derived IL-13
cannot stimulate alternative activation of PPAR-δ-deﬁcient myeloid
cells and results in inﬂammation andmetabolic dysfunction in adipose
tissue and liver. Additionally, Odegaard et al. [21] demonstrated that
loss of PPAR-δ in lean mice impairs alternative activation of Kupffer
cells, which results in decreased oxidative metabolism, hepatic
steatosis and increased systemic insulin resistance. Clariﬁcation of
the involvement of PPAR-γ and PPAR-δ is needed, however, as
Marathe et al. [22] reported that neither PPAR-γ nor PPAR-δ was
required for alternative activation.
Given the active involvement of the adipose tissue-associated
macrophages and circulating monocyte [23] populations in chronic
inﬂammation of obesity, this current study was designed to
investigate the role of the hepatic macrophage, or Kupffer cell, in
the inﬂammatory and insulin resistant states of obesity. Kupffer cells
are the largest macrophage population in the body [24] and, in
addition to fulﬁlling a variety of other immunologic functions [25,26],
are the primary innate immune defense against exposure to foreign
antigens from the diet and intestinal tract [26,27].
In contrast to the active characterization of adipose tissue-
associated macrophages, there are few studies addressing the role
of Kupffer cells in the inﬂammatory and metabolically dysfunctional
obese state. While the work by Odegaard et al. [21] suggested that an
alternatively activated Kupffer cell may support hepatic insulin
responsiveness, the effect of obesity on the native Kupffer cell
population remains undeﬁned. The results of this investigation
indicate that in contrast to adipose tissue-associated macrophages,
Kupffer cells do not signiﬁcantly contribute to the chronic proin-
ﬂammatory environment of obesity. In support of observations by
Odegaard et al. [21], Kupffer cells may partially protect hepatocytes
from the inﬂammatory milieu and the subsequent steatosis and
insulin resistance associated with high-fat diet-induced obesity.
2. Materials and methods
2.1. Antibodies
Phospho-speciﬁc Akt (serine 473), phospho-speciﬁc STAT3 (tyro-
sine705) and STAT3 antibodies were purchased from Cell Signaling
Technology (Beverly, MA). An anti-phosphotyrosine antibody was
purchased fromMillipore (Billerica, MA). Akt1/2 and insulin receptor
beta chain antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA).
2.2. Animals
Male C57BL/6J mice purchased from Jackson Laboratories were
housed 4 per cage in a microisolator room on a 12-h light/dark cycle
at the University of Rochester. The University Committee on Animal
Resources approved all protocols. 4-week-old C57BL/6J male mice
were fed standard chow or a high-fat diet (16.6% kcal/gm protein,
59.3% kcal/gm fat, 24.48% kcal/gm carbohydrate) (Bioserve #S3282,
Frenchtown, NJ). The latter resulted in diet-induced obesity. With
the exception of the animals used for metabolic challenge tests,
mice were utilized for experimentation after 15–17 weeks on the
high-fat diet. Interleukin-10 knockout mice (B6.129P2-IL10tm1cgn/J)
and wild-type controls were purchased from Jackson Laboratories
and housed according to the conditions above. High-fat feeding of
this model began at 4 weeks of age and experiments were per-
formed after 7–8 weeks.2.3. Metabolic studies
Metabolic studies were performed after 12–14 weeks of high-fat
diet and 36 h following PBS- or clodronate-containing liposome
administration. Brieﬂy, mice were fasted overnight and given an
intraperitoneal injection of insulin (1.5U/kg), glucose (1.5 g/kg), or
pyruvate (1.0 g/kg) dissolved in sterile saline. Blood was taken from
tail vein every 15 min and glucose was measured with an Accu-chek
Advantage® glucometer (Accu-chek). Results were normalized to
percent starting (fasted) glucose and area under the curve (AUC) was
calculated.
2.4. Kupffer cell ablation and immunostaining
Phosphate-buffered saline (PBS)-containing and clodronate-con-
taining liposome suspensions were prepared as described earlier [28].
All parameters were assessed at 36 h following a 200-μl intra-
peritoneal injection. Liver slices were formalin-ﬁxed, parafﬁn-em-
bedded, and sectioned. Sections were stained using rat anti-mouse
F4/80 (Invitrogen, Carlsbad, CA) antibody at 1:50 dilution. Detection
was achieved using a biotin-conjugated rabbit anti-rat antibody
(Vector Laboratories Inc., Burlingame, CA), incubation with strepta-
vidin-horseradish peroxidase (Jackson Labs), exposure to ami-
noethylcarbazole (Dako, Carpinteria, CA), and hematoxylin blue
counterstaining.
2.5. Assessment of in vivo insulin signaling
Following an overnight fast (∼15 h), animals were brieﬂy
anesthetized using an isoﬂuorane vaporizer (Summit Medical,
Salem, OR), and injected intraperitoneally with vehicle (sterile
saline) or 1.5 Units/kg Novolin® human insulin (Novo Nordisk
Pharmaceuticals, Princeton, NJ). After 10 min, animals were sacri-
ﬁced. Harvest and processing of frozen tissue for immunoprecipita-
tion and quantitative immunoblotting were carried out as previously
described [29].
2.6. Lipid extraction and analysis
Lipid extraction protocol was adapted from [30]. Brieﬂy, frozen
liver fractions were weighed and homogenized in chloroform:
methanol (2:1 vol/vol). Extracts were passed through ﬂuted ﬁlter
paper. Saline/0.05% sulfuric acid was added to partition the
chloroform at a ratio of 1:5 (vol/vol) of ﬁltered extract. Partitioning
of extracts was completed by centrifugation, and the chloroform layer
was removed, dried down and resuspended in fresh chloroform.
Samples were diluted in 5% (vol/vol) Triton X-100 (Sigma) in
chloroform and evaporated. Lipids were measured using L-Type Tg
and Cholesterol E kits from Wako Chemicals USA (Richmond, VA) in
duplicate. Total lipid was normalized to protein content per wet
weight of sample tissue. Oil Red O staining was performed on frozen
liver sections and counterstained with hematoxylin.
2.7. Serum collection and analysis
Blood was collected via cardiac puncture, allowed to clot for
30 min, and spun at 7000 rpm for 10 min. Isolated serum was stored
at −80 °C. Triglyceride and cholesterol levels were measured by the
automated clinical laboratories at the University of Rochester. PAI-1,
MCP-1, leptin, resistin, and insulin levels were determined using a
LINCOplex™ (LINCO Research, Inc, St. Charles, MO) mouse serum
adipokine kit on the Bio-Rad Bio-Plex™ 200 Suspension Array
System. IL-6 levels were determined using a Luminex® Beadlyte®
(Upstate, Lake Placed, NY) assay. Blood glucose was measured from
tail vein using an Accu-chek Advantage® glucometer (Accu-chek)
and HOMA-IR (homeostasis model assessment of insulin resistance)
Fig. 1. Diet-induced obesity does not induce Kupffer cell expansion or activation.
C57BL/6J mice were fed a normal chow (lean) or high-fat diet (DIO) ad libitum for
15 weeks. Realtime RT-PCR was performed on RNA extracted from liver tissue. Markers
of macrophage presence (Emr1, Cd68) and recruitment (Ccl2) (A), inﬂammatory
cytokines (B), and alternative activation (C) were measured in the liver of lean and DIO
mice. Arg1 (arginase 1); Chi3l3 (chitinase 3-like 3);Mgl1 (macrophage galactose N-acetyl-
galactosamine speciﬁc lectin 1); Mrc2 (mannose receptor, C type 2); Ppard (PPARδ), Il4
(interleukin-4). All markers were normalized to expression of 36B4. Lean mice:
mean±S.E. n=10. DIO mice: mean±S.E. n=9. ⁎p≤0.05; ⁎⁎p≤0.01.
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(μU/ml)/22.5 [31].
2.8. Real-time PCR analysis
RNA was extracted using TRIzol® (Invitrogen) according to the
manufacturer's directions. Reverse transcription was performed using
iSCRIPT™ (Bio-Rad). TaqMan probes for Actb, Ccl2, Emr1, Il6, Il10,
Socs3, Tnfa, and Hp were purchased from Applied Biosystems and
used with TaqMan 2× Master Mix (Applied Biosystems). Primer
sequences for assays using Sybr Green (Bio-Rad) can be found in the
Supplementary Table. The samples were run on an iCycler IQ real-
time PCR detection system (Bio-Rad) and calculations determined as
previously described [32].
2.9. Statistical analysis
Statistical analysis was performed using StatView 5 software (SAS
Institute, Cary, NC) and Microsoft Excel (2004). Experimental outliers
were calculated and removed using interquartile range calculations.
Experimental means were compared using ANOVA where sample
means from four groups were compared and Student t-test for
comparing two groups.
3. Results
3.1. Diet-induced obesity does not increase hepatic Kupffer cell markers
or result in classical activation of Kupffer cells
C57BL/6J mice were fed a normal chow (lean) or high-fat diet for
15 weeks to promote diet-induced obesity (DIO). Levels of two
macrophage markers, F4/80 and CD68, were used to assess resident
hepatic Kupffer cells. Expression of Emr1 (F4/80) and Cd68 remained
unaltered in DIO mice (Fig. 1A). Hepatic expression of Ccl2 (MCP-1)
(Fig. 1A) and inﬂammatory cytokines Il6, Tnfa (TNF-α), and Il10 (Fig.
1B) also remained essentially unaltered following high-fat feeding.
These data suggest that the Kupffer cell population is not expanded in
DIO mice and that the liver may not be directly contributing to the
chronic inﬂammatory state of obesity.
Given the absence of increased inﬂammatory cytokine production,
hepatic markers of alternative activation were examined. Expression
of Chi3l3 (chitinase 3-like 3), Mgl1 (macrophage galactose N-acetyl-
galactosamine speciﬁc lectin 1), and Mrc2 (mannose receptor, C type
2) were all modestly elevated in the liver of DIO mice (Fig. 1C). DIO
mice also displayed a 40% increase in expression of Ppard (PPARδ),
which Odegaard et al. [21] demonstrated to be required for alternative
activation. Expression of IL-4, a cytokine produced by alternatively
activated macrophages, was also increased in DIO liver. Expression of
arginase 1, a major product of alternative activation remained
unaltered. Collectively, these results indicate an increase in alterna-
tive activation markers in the liver of DIO mice, which may have
functional relevance in this metabolic condition as the results of
Odegaard et al. [21] suggest. Since the C57BL/6 strain has impaired
alternative activation, the magnitude of activation may not be as
robust as that observed in other strains, such as the Th2-prone Balb/c
line [33].
In contrast to the liver, the adipose tissue of the DIOmice displayed
increased expression of macrophage markers and increased inﬂam-
matory cytokine expression. Adipose tissue expression of macrophage
markers, Emr1 and Cd68, increased 4- and 7-fold, respectively, in DIO
mice compared to lean controls (Supplementary Fig. 1A). Expression
of Ccl2 was 5-fold elevated, although this induction did not reach
statistical signiﬁcance. A 3-fold induction of Tnfa was observed, while
Il6 and Il10 also trended upwards, indicating an active inﬂammatory
environment (Supplementary Fig. 1B). As anticipated, the active
inﬂammatory response within the adipose tissue of high-fat-fed miceis associated with increased weight gain (Supplementary Fig. 1C),
impaired systemic glucose tolerance (Supplementary Fig. 1D),
increased homeostatic model assessment of insulin resistance
(HOMA-IR) (Supplementary Fig. 1E), and increased hepatic triglycer-
ide accumulation (Supplementary Fig. 1F).
3.2. Kupffer cell ablation using clodronate-containing liposomes
Diet-induced obesity did not expand or classically activate the
Kupffer cell population, but increased expression of markers of
alternative activation was observed relative to lean controls (Fig.
1C). To more directly examine the role of Kupffer cells in obesity and
expand upon the observation that alternatively activated Kupffer cells
have the potential to protect against obesity-associated inﬂammation,
steatosis, and insulin resistance [21], awell-characterizedmacrophage
Table 1
Serum parameters in DIO mice, 36 h after CLD liposome administration.
PBS liposomes CLD liposomes
PAI-1 3.5±0.52 ng/ml 4.7±1.12 ng/ml p=0.345
MCP-1 17.3±1.87 pg/ml 46.6±7.78 pg/ml p=0.002
Leptin 8.2±1.23 ng/ml 11.1±1.70 ng/ml p=0.192
Resistin 2.0±0.34 ng/ml 1.9±0.44 ng/ml p=0.922
IL-6 13.8pg/ml ±2.68 pg/ml 19.2pg/ml ±11.27 pg/ml p=0.657
IL-10 17.1pg/ml ±2.41 pg/ml 14.4pg/ml ±4.82 pg/ml p=0.607
Triglyceride 117.2±10.4 mg/dl 124.3±8.6 mg/dl p=0.631
Cholesterol 148±6.3 mg/dl 174.3±4.1 mg/dl p=0.014
Fasted glucose 130±16 mg/dl 172±21 mg/dl p=0.126
Fasted insulin 0.28±0.07 ng/ml 0.76±0.3 ng/ml p=0.004
Plasminogen activator inhibitor 1 (PAI-1), monocyte chemoattractant protein (MCP-1),
leptin, and resistin weremeasured in serum using Bio-plex™ technology (Bio-Rad). IL-6
and IL-10 were measured using Luminex® Beadlyte® technology (Upstate). All values
are the mean±S.E. of n≥6. Triglyceride and cholesterol values are the mean±S.E. of
n≥4. Fasted glucose and insulin values are the mean±S.E. of n≥5.
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injected clodronate-containing (CLD) liposomes are phagocytized by
Kupffer cells (and peritoneal macrophages), resulting in cellular
apoptosis [28,34]. Using this approach, nearly complete ablation of
Kupffer cells was achieved 36 h post-injection in lean and DIO mice.
This was conﬁrmed by a loss of F4/80 staining by immunohistochem-Fig. 2. Loss of Kupffer cells results in increased STAT3-dependent signaling in lean and DIOmi
containing or clodronate (CLD)-containing liposomes. RNA was extracted from the liver and
(mean±S.E. n≥6) and (B) DIO (mean±S.E. n≥16) mice. Hepatic IL-6-responsive genes (H
assessed in lean (C) (mean±S.E. n≥9) and DIO (D) (mean±S.E. n≥4) mice and normalize
performed on liver extracts from lean (C) (mean±S.E. n≥4) and DIO (D) (mean±S.E. n
presented. ⁎p≤0.05; ⁎⁎p≤0.01.istry in clodronate-treated liver sections (Supplementary Fig. 2A) and
a 98% (lean) and 96% (DIO) loss of Emr1 expression (Supplementary
Fig. 2B). Comparable F4/80 staining in lean and DIO liver from PBS-
injected animals supports the interpretation that the Kupffer cell
population did not expand with high-fat feeding. CLD liposomes did
not disrupt adipose tissue macrophages of lean animals, but a 2-fold
increase in DIO adipose tissue-associated Emr1 expression was
observed (Supplementary Fig. 2B). This latter effect in DIO mice was
not associated with increases in circulating levels of IL-6 (Table 1) or
inﬂammatory cytokine-dependent target gene expression in adipose
tissue (Supplementary Fig. 2C).
3.3. Loss of Kupffer cells alters the local hepatic inﬂammatory
environment of lean and DIO mice
Kupffer cell ablation in lean mice reduced hepatic expression of Il6
(73%) and Tnfa (46%) (Fig. 2A). Expression of Il6 was reduced by 52%
in DIO mice following Kupffer cell ablation, but Tnfa expression
remained unaltered (Fig. 2B). A striking 95% and 84% loss of IL-10
expression in lean and DIO mice, respectively, indicates that Kupffer
cells are the primary source of this anti-inﬂammatory cytokine in the
liver (Fig. 2A, B).
Although Kupffer cell ablation did not increase hepatic cytokine
production, a selective increase in hepatic STAT3 signaling wasce. Lean and DIOmice were sacriﬁced 36 h following an intraperitoneal injection of PBS-
realtime RT-PCR was performed for expression of inﬂammatory cytokines in (A) lean
p, Socs3, Orm1, Saa) and TNF-α-responsive genes (Traf1, Nfkbia, Rela, Ikbkb) were also
d to 36B4 expression. Western blot analysis for phosphorylation of STAT3 (Y705) was
=12) mice and compared to total STAT3 protein. Representative Western blots are
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was increased in both lean (Fig. 2C) and DIO (Fig. 2D) mice following
Kupffer cell ablation. Acute phase protein family members haptoglo-
bin (Hp), orosomucoid-1 (Orm1), and serum amyloid A (Saa) were
approximately 2-, 3-, and 7-fold elevated in lean mice following CLD
liposome administration (Fig. 2C). Elevations of these markers were
also observed in Kupffer cell ablated DIO mouse livers, with a
signiﬁcant 3-fold increase in suppressor of cytokine signaling (SOCS)-
3 (Fig. 2D). In contrast, downstream transcriptional targets of TNF-α
or endotoxin via NFκB signaling [35–37] including Traf1, Nfkbia
(IκBα), Rela, and Ikbkb (IKKβ) were collectively unchanged in lean
liver (Fig. 2C). With the exception of a modest increase in Traf1, they
were also unchanged in DIO liver (Fig. 2D). Since IL-6 gene expression
within the liver actually trended downward, the increased STAT3-
dependent signaling may reﬂect decreased feedback inhibition of the
pathway and/or a response to increased circulating STAT3 agonist.
To explore this possibility, serum cytokine and adipokine
markers were assessed in DIO mice following Kupffer cell ablation.
Circulating levels of IL-6 and IL-10 in DIO mice remained unaltered
following Kupffer cell ablation (Table 1). TNF-α levels were not
detectable. No change in the inﬂammatory marker PAI-1 or
adipokine markers (leptin, resistin) was observed. Interestingly,
circulating levels of MCP-1 were signiﬁcantly elevated, possibly
reﬂecting a replenishment mechanism following Kupffer cell
ablation. While cholesterol levels were elevated, circulating triglyc-
eride levels remained unchanged.Fig. 3. Kupffer cell ablation in DIO mice is associated with altered hepatic lipid content. He
assessed 36 h following Kupffer cell ablation. (A) Representative Oil Red O stained liver se
(B) Lipids were extracted from frozen livers of lean (mean±S.E. n=8) and DIO (mean±S.E
(mg/wet weight).3.4. Kupffer cell ablation in DIO mice results in increased hepatic
lipid accumulation
The reports of Odegaard et al. [21] and Kang et al. [20] suggested
that cross-talk between Kupffer cells and hepatocytes could inﬂuence
hepatic lipid metabolism. It was further proposed that Kupffer cells
may protect hepatocytes from steatosis. To test this hypothesis, the
impact of Kupffer cell ablation on obesity-associated alterations in
lipid metabolism was examined. Lipid accumulation as a result of
high-fat feeding was visible by Oil Red O staining in DIO liver sections
compared to the lean controls (Fig. 3A). This increase is displayed
quantitatively in Supplementary Fig. 1F. No qualitative or quantitative
change in lipid accumulation was observed in livers of lean mice
following Kupffer cell ablation (Fig. 3A and B). Kupffer cell ablation in
DIO mice, however, increased hepatic triglyceride accumulation
beyond that caused by high-fat feeding alone (Fig. 3A and B).
Although serum cholesterol was increased in DIO mice upon Kupffer
cell ablation, total hepatic cholesterol remained unaltered
(PBS=1.00±0.11, CLD=1.03±0.14, p=0.86). These results sup-
port the proposal that Kupffer cells partially protect hepatocytes from
dysregulation of hepatic lipid metabolism and steatosis associated
with obesity. Protein and gene expression of several lipid metabolic
targets was analyzed in the livers of DIO control and DIO Kupffer cell-
ablated mice and displayed in Supplementary Fig. 3. Of the oxidation,
synthesis, and secretion-related markers, only PPARγ mRNA was
elevated (Supplementary Fig. 3B). Since the modest elevation was notpatic lipid content in normal chow-fed (lean) and diet-induced obese (DIO) mice was
ctions (20x) are displayed from mice treated with PBS- or CLD-containing liposomes.
. n=6) mice. Triglyceride content (mg/wet weight) was normalized to protein content
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observation is unclear.
3.5. Kupffer cell ablation in DIO mice impairs hepatic insulin signaling
Given that several reports link IL-6-induced STAT3-dependent
signaling and hepatic lipid accumulation with insulin resistance
[5,29,38], it would be predicted that hepatic insulin signaling would
decrease in a Kupffer cell-ablated liver. To test this hypothesis, hepatic
response to an insulin bolus was assessed following Kupffer cell
ablation. Despite increased STAT3-dependent signaling in Kupffer
cell-ablated lean mice, no change in insulin-stimulated insulin
receptor autophosphorylation or serine phosphorylation of the
downstream signaling mediator Akt was observed (Fig. 4A). In DIOFig. 4. Kupffer cell ablation in DIO mice is associated with impaired hepatic insulin signalin
an i.p. insulin bolus (1.5 Units/kg). Tissues were harvested after 10 min. Tyrosine phospho
Western blot analysis in livers of lean (A) and DIO (B) mice. IR was immunoprecipitated pri
blots are used to conﬁrm comparable loading. Representative blots are shown. PBS=PBS-mice, where both STAT3-dependent signaling and increased steatosis
were observed, insulin receptor autophosphorylation and Akt serine
phosphorylation were reduced 30% and 40%, respectively, upon
Kupffer cell ablation (Fig. 4B). These results indicate that increased
triglyceride in combination with increased STAT3-dependent signal-
ing is associated with suppressed hepatic insulin signaling following
Kupffer cell ablation in DIO mice.
3.6. Kupffer cell ablation in DIO mice and systemic response to insulin
Given that clodronate-treated DIO mice displayed impaired
hepatic insulin signaling, systemic response to metabolic stimuli
was assessed in these mice. Kupffer cell ablation in DIO mice resulted
in an increase in HOMA-IR, an index of insulin resistance (Fig. 5A).g. Following Kupffer cell ablation and an overnight fast, lean and DIO mice were given
rylation of the insulin receptor (IR) and Akt Ser473 phosphorylation were assessed by
or to blotting. Each bar represents the mean±S.E. of n≥7 (lean) and n≥9 (DIO). Mass
containing liposomes. CLD=clodronate-containing liposomes. ⁎p≤0.05; ⁎⁎p≤0.01.
Fig. 5. Kupffer cell ablation in DIO mice has minor impact on systemic insulin response. DIO mice were Kupffer cell ablated and fasted overnight prior to i.p. injection of glucose,
insulin, or pyruvate. Blood glucose was measured from tail vein at 15-min intervals. (A) HOMA-IR determined from fasted serum insulin and glucose measurements. PBS n=10; CLD
n=7. (B) Insulin tolerance test (ITT) in response to 1.5U/kg insulin. (C) Glucose tolerance test (GTT) in response to 1.5 g/kg glucose. (D) Pyruvate tolerance test (PTT) in response to
1.0 g/kg sodium pyruvate. Results for ITT are normalized to percent starting (fasted) glucose. AUC is plotted for each challenge test. For tolerance tests, PBS n=5; CLD n≥5.
PBS=PBS-containing liposomes. CLD=clodronate-containing liposomes. ⁎p≤0.05.
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levels (Table 1). In agreement with this result, Kupffer cell ablation of
DIO mice modestly impaired insulin-stimulated glucose uptake, but
area under the curve (AUC) did not show a signiﬁcant effect (Fig. 5B).
Response to a glucose bolus was similar in PBS and clodronate-treated
DIO mice (Fig. 5C). A pyruvate tolerance test revealed prolonged
circulating glucose in response to an i.p. injection of pyruvate in the
clodronate-treated animals, but this effect did not reach signiﬁcance
(Fig. 5D). These results indicate that Kupffer cell ablation in DIO miceis associated with increased insulin resistance but only minor
impairment in metabolic challenge tests.
3.7. Systemic loss of IL-10 during diet-induced obesity
Wehypothesized that loss of Kupffer cell-derived IL-10may locally
or systemically contribute to dysregulation of STAT3 signaling and
lipid metabolism in diet-induced obesity. To address this, IL-10
knockout mice (IL-10KO) and matched controls (WT) were subjected
Fig. 6. DIO IL-10 knockout mice do not display altered hepatic insulin responsiveness. IL-10 knockout (IL-10KO) and wild-type (WT) mice were fed a high-fat diet for 8 weeks. (A) HOMA-IR was calculated from glucose and insulin
concentrations of 16-h fasted WT and IL-10KO mice (mean±S.E. of n≥4). (B) Western blot analysis for phosphorylation of STAT3 (Y705) was performed on whole cell extracts fromWT and IL-10KO mouse liver. Hepatic expression of IL-6-
responsive genes and TNF-α-responsive genes was assessed by realtime RT-PCR (mean±S.E. of n=6). (C) Hepatic cytokine expression was assessed by realtime RT-PCR (mean±S.E. of n=6). Circulating IL-6 levels were measured by a
Luminex® Beadlyte® assay (mean±S.E. of n=6). (D) Hepatic triglyceride content (mg/wet weight) was quantiﬁed inWT and IL-10KOmice and normalized to protein (mg/wet weight) (mean±S.E. of n=11). High-fat-fedWT and IL-10KO
mice were fasted overnight prior to an i.p. injection of insulin (1.5 Units/kg). Tissues were harvested after 10 min. (E) Tyrosine phosphorylation of the insulin receptor (IR) and Akt Ser473 phosphorylation in livers of WT and KO mice were
assessed by Western blot analysis (mean±S.E. of n=6). IR was immunoprecipitated prior to blotting. IR and Akt mass blots are included for comparison. ⁎p≤0.05; ⁎⁎p≤0.01.
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to Kupffer cell ablation studies (15–17 weeks), was employed to
minimize colitis that develops progressively in the IL-10KO mouse
model [39]. Induction of insulin resistancewas conﬁrmed by increased
HOMA-IR in high-fat diet-fed WT and IL-10KO mice compared to lean
controls (Fig. 6A). No signiﬁcant difference inHOMA-IRor bodyweight
(DIOWT=30.3 g±1.1; DIO IL-10KO=33.4±1.3; p=0.09)was seen,
however, between obese WT and IL-10KO mice. Systemic deletion of
IL-10 in an obese mouse resulted in increased hepatic STAT3
phosphorylation and 2.5- and 2-fold increases in hepatic Socs3 and
Saa expression, respectively (Fig. 6B). These increases occurred in
the absence of increased hepatic Il6 message or an increase in
circulating IL-6 levels (Fig. 6C). Circulating IL-6 levels actually
decreased in obese IL-10KO mice. Although the magnitude of hepatic
acute phase protein gene inductionwas less than that observed in lean
and DIO mice following Kupffer cell ablation (Fig. 2C, D), these data
again suggest an association between loss of IL-10 and increased
hepatic STAT3-dependent signaling in high-fat diet induced obesity.
Despite a modest reduction in Rela, hepatic expression of most NFκB-
responsive genes remained unaltered (Fig. 6B). A statistically
signiﬁcant increase in hepatic triglyceride content was also observed
in the livers of the high-fat diet-fed IL-10KO mice compared to their
WT counterparts (Fig. 6D). Systemic loss of IL-10 in an obese state,
however, did not alter hepatic insulin signaling compared to WT
controls (Fig. 6E). Thus, while loss of IL-10 by gene deletion or Kupffer
cell ablation is associated with altered hepatic STAT3 signaling, acute
phase protein induction, and increased hepatic lipid accumulation,
loss of additional Kupffer cell factors are required to further impair
obesity-associated hepatic insulin signaling.
4. Discussion
Obesity-mediated insulin resistance has been shown to have a
strong inﬂammatory component. Several groups, including Weisberg
et al. [11] and Xu et al. [9], have suggested an important role for the
adipose tissue-associatedmacrophage inmediating this inﬂammatory
state and subsequent insulin resistance. In contrast to the character-
ization of the adipose tissue-associated macrophages, the effect of
obesity on the Kupffer cell population is poorly understood. The
current study investigated the role of liver macrophages, or Kupffer
cells, in a diet-induced obese mouse model of hepatic inﬂammation
and insulin resistance. Our results support the conclusion that Kupffer
cells do not contribute to the proinﬂammatory environment of obesity,
but modulate STAT3-dependent signaling and obesity-associated
impairment of hepatic lipid metabolism and insulin resistance.
Here we report similar levels of macrophage markers, Emr1 and
Cd68, in livers of lean and obese mice, suggesting no expansion of
the Kupffer cell population in obesity. F4/80 staining of liver samples
from lean and DIO mice supports this interpretation. This is also
supported by the observations of Weisberg et al. [11] and Xu et al. [9]
who reported similar Kupffer cell numbers despite an increased
adipose tissue-associated macrophage population. Cintra et al. [40]
and Cai et al. [41], however, report increased Kupffer cell numbers in
mice placed on a high-fat diet for 2 and 3 months, respectively. The
use of the Swiss mouse strain by Cintra et al. [40] could account for
some of this difference, as mouse strains display varied phenotypes. A
variation in diet composition, such as the ratio of saturated to
unsaturated fat [42], could play a role in the obesity-associated effects
seen by Cai et al. [41], but this dietary information was not provided.
In addition to no change in Kupffer cell markers in the liver
following high-fat feeding, the absence of a change in hepatic
inﬂammatory cytokine expression suggests that Kupffer cells are not
actively contributing to the proinﬂammatory environment of diet-
induced obesity. A collective increase in expression of alternative
activationmarkers suggests that hepatic macrophages do not respond
to the Th1 polarizing environment of obesity. These data are incontrast to adipose tissue-associated macrophages which undergo a
Th2 to Th1 switch [13] and actively increase production of
inﬂammatory cytokines. Other hepatic immune populations like
CD4+NK1.1 cells can mediate alternative activation of Kupffer cells
in response to inﬂammation [43]. Perhaps they also mediate a similar
Kupffer cell activation in response to the adipose tissue-derived
cytokines and hepatic lipid accumulation.
Kupffer cell-ablated and IL-10KO DIO mice displayed increased
hepatic STAT3-dependent signaling. In all cases, this occurred in the
absence of increased hepatic IL-6 message, but a dramatic (≥90%)
reduction of IL-10. Since IL-10 is an antagonist of IL-6 signaling, we
hypothesize that Kupffer cell-derived IL-10 could modulate this
response. This observation does not rule out a role for other Kupffer
cell-derived direct or indirect cellular mediators of hepatocyte STAT3
signaling. Kupffer cell-derived molecules could be inducing inhibitors
of IL-6 or other STAT3-dependent effectors within the hepatocyte,
such as protein inhibitor of activated STAT3 (PIAS3), SH2-domain-
containing tyrosine phosphatase (SHP2), or p38 stress kinase [44–46].
Alternatively, increased shedding or expression of soluble IL-6
receptor alpha (soluble gp80) following Kupffer cell ablation, could
sensitize hepatocytes to circulating IL-6 and increase acute phase
protein production [47,48]. Endotoxin stimulation of CD14 has been
reported to activate the acute phase response, especially in the obese
state [49], but this seems unlikely in our models as NFκB transcrip-
tional markers remained unaltered.
Both loss of Kupffer cells and systemic absence of IL-10
exacerbated hepatic triglyceride accumulation (steatosis) associated
with obesity. This suggests that Kupffer cells and/or IL-10 production
impart partial protection against pathologic accumulation of hepatic
lipid. In support of this premise, inhibition of Kupffer cells has been
shown to decrease PGE2 release within the liver leading to increased
hepatic lipid synthesis [50]. In agreement with our DIO IL-10KO
model, den Boer and associates also observed that systemic loss of IL-
10 during obesity results in hepatic triglyceride accumulation [51].
Loss of IL-10 and increased hepatic STAT3-dependent signaling in our
model is not sufﬁcient, however, for increased hepatic lipid
accumulation, as lipid content remained unaltered following Kupffer
cell ablation in lean mice. A high-fat diet appears to also be necessary.
These observations do not rule out the possibility that other Kupffer
cell-derived factors could be directly involved in hepatic triglyceride
synthesis or secretion during obesity.
Experimental evidence demonstrates that chronic inﬂammation
and altered lipid metabolism associated with obesity directly impair
insulin signaling. While many cytokines are involved in the chronic
inﬂammation of obesity, IL-6 appears to be a major effector inhibiting
insulin signaling in the liver at least in part through SOCS-3 induction
[5,52,53]. Lipid accumulation induces oxidative stress and activates
serine kinases that impair the insulin-signaling cascade [54–56]. Our
Kupffer cell-ablated DIO mice displayed signiﬁcant increases STAT3-
dependent signaling and hepatic triglyceride accumulation. As a
result, we hypothesized that insulin signaling would be impaired in
this model. Hepatic response to an insulin bolus following Kupffer cell
ablation was impaired 30-40% in association with a 3-fold increase in
expression of Socs3 in the DIO mice. Despite an increase in HOMA-IR,
systemic response to insulin, glucose, or pyruvate was not signiﬁ-
cantly altered following ablation in DIO mice. These data would
suggest that Kupffer cells promote local hepatic insulin action. Since
Kupffer cell ablation in lean mice elevated STAT3-dependent gene
expression in the absence of impaired insulin signaling, increased
STAT3-dependent signaling alone is not sufﬁcient to impair insulin
signaling in this model.
Recently, Cintra et al. [40] observed that treatment of DIO Swiss
mice with IL-10 neutralizing antibodies or suppressing its expression
using antisense techniques increased inﬂammation and impaired
insulin responsiveness. In support of this premise, increased IL-10
expression levels in humans have been correlated with increased
1071A.H. Clementi et al. / Biochimica et Biophysica Acta 1792 (2009) 1062–1072insulin sensitivity [57]. While infusion of IL-6 into mice impaired
insulin responsiveness during a hyperinsulinemic, euglycemic clamp
study, co-infusion of IL-10was shown to overcome the IL-6 effect [58].
In contrast to this, insulin signaling remained unaltered in our DIO IL-
10KO mouse model. This agrees with the observation by den Boer et
al. [51] that DIO IL-10 knockout mice displayed altered hepatic lipid
metabolism, but unaltered insulin action compared to high-fat-fed
wild-type controls. Additional work is needed to clarify the relation-
ship between IL-10, inﬂammation, and insulin signaling.
Our observations indicate that while IL-10 is associated with
modulation of hepatic STAT3-dependent signaling and lipid metab-
olism in DIO mice, one or more additional Kupffer cell mediators is
necessary to partially preserve insulin responsiveness. Reactive
oxygen species and ER stress have been directly implicated in the
induction of insulin resistance in hepatocytes [55,59]. Kupffer cell-
produced anti-oxidative molecules are potential direct or indirect
protective mediators. Activation of the powerful anti-oxidant heme
oxygenase-1 (HO-1) [60] reduces obesity-associated inﬂammation
and improves systemic insulin responsiveness in mouse and rat
models [61,62]. Kupffer cells produce HO-1, which has been
demonstrated to protect against endotoxemia and oxidative stress
in a rat model of ischemia-reperfusion [63]. Kupffer cell ablation may
alter synthesis of another powerful anti-oxidant, lipoic acid, which
can dampen macrophage inﬂammatory responses [64] and has also
been implicated in protection against oxidative stress-induced insulin
resistance [65,66]. Cyclooxygenase (COX) 1/2 and prostaglandin E2
(PGE2) appear to be integral to resolution of an inﬂammatory
response [67] and lipid accumulation [50]. Both of these latter
responses appear to be required for impairment of insulin signaling in
our DIO Kupffer cell ablation model.
Very recently, Neyrinck et al [68] demonstrated that inhibition of
Kupffer cells in DIO mice by i.p. injection of gadolinium chloride
improves HOMA-IR and systemic glucose tolerance in association with
reduced hepatic steatosis. While these results are contrary to those
reported here, there are important limitations to the gadolinium
chloride model that may account for this difference. Gadolinium
chloride treatments are associated with hepatocyte proliferation [69].
Gadolinium chloride toxicity and mineral deposition in liver and
stomach of rodents has also been documented by Spencer et al. [70]
following single injections. The markedly reduced weight gain on a
high-fat diet observed by Neyrinck et al [68] in mice receiving twice
weekly gadolinium chloride injections for 3 weeks may be related to
these tissue changes. Improved insulin sensitivity andglucose tolerance
in gadolinium chloride-treated DIOmice could be due to the decreased
weight gain independent of changes in Kupffer cell function.
In summary, the results of this investigation indicate that Kupffer
cells resist classical activation and do not contribute to the
proinﬂammatory state of high-fat diet-induced obesity. Loss of
Kupffer cells in obesity results in a marked loss of hepatic IL-10
expression that is associated with increased hepatic STAT3-depen-
dent signaling and increased lipid accumulation. Kupffer cell loss in
DIO mice is also associated with decreased hepatic insulin receptor
signaling. Future investigations are necessary to elucidate the
mechanism of these Kupffer cell-dependent effects.
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